(Redirected from
Atypical adenomatous hyperplasia of the lung)
Atypical adenomatous hyperplasia is a subtype of pneumocytic hyperplasia in the lung. It can be a precursor lesion of in situ adenocarcinoma of the lung ( bronchioloalveolar carcinoma). In prostate tissue biopsy, it can be confused for adenocarcinoma of the prostate. The needle biopsy rate is less than 1%.
Pathology
Morphological differential diagnosis
- Multifocal micronodular pneumocyte hyperplasia (MMPH) [1]
- in situ pulmonary adenocarcinoma ( bronchioloalveolar carcinoma – BAC)
Variants
Histopathological images
_localized_noninvasive_type.jpg)
_localized_noninvasive_type.jpg)
_localized_noninvasive_type.jpg)
_localized_noninvasive_type.jpg)
See also
References
- ^ Kobashi, Y; Sugiu, T; Mouri, K; Irei, T; Nakata, M; Oka, M (2008). "Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis: Differentiation from multiple atypical adenomatous hyperplasia". Japanese Journal of Clinical Oncology. 38 (6): 451–4. doi: 10.1093/jjco/hyn042. PMID 18535095.
- ^ Kobashi, Y; Sugiu, T; Mouri, K; Irei, T; Nakata, M; Oka, M (2008). "Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis: Differentiation from multiple atypical adenomatous hyperplasia". Japanese Journal of Clinical Oncology. 38 (6): 451–4. doi: 10.1093/jjco/hyn042. PMID 18535095.
- ^ Pastorino, U; Calabrò, E; Tamborini, E; Marchianò, A; Orsenigo, M; Fabbri, A; Sozzi, G; Novello, S; De Marinis, F (2009). "Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib". Journal of Thoracic Oncology. 4 (2): 266–7. doi: 10.1097/JTO.0b013e3181952930. hdl: 2318/84918. PMID 19179908. S2CID 35747902.
 | This medical sign article is a stub. You can help Wikipedia by expanding it. |